BRIEF-Tg Therapeutics Provides Preliminary Fourth Quarter And Full Year 2025 Results

Reuters01-14

BRIEF-Tg <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Provides Preliminary Fourth Quarter And Full Year 2025 Results

Jan 13 (Reuters) - TG Therapeutics Inc TGTX.O:

TG THERAPEUTICS PROVIDES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2025 NET PRODUCT REVENUE AND 2026 REVENUE GUIDANCE AND ANTICIPATED DEVELOPMENT MILESTONES
TG THERAPEUTICS INC - 2026 GLOBAL REVENUE TARGET $875-900 MILLION, BRIUMVI U.S. $825-850 MILLION
TG THERAPEUTICS INC - PHASE 1 AZER-CEL DATA IN PROGRESSIVE MS EXPECTED SECOND HALF 2026

Source text: ID:nGNX6BPwLK

Further company coverage: TGTX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603553376?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 06:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603553376","market":"nz","top_or_hot":-1,"title":"BRIEF-Tg Therapeutics Provides Preliminary Fourth Quarter And Full Year 2025 Results","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Tg <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Provides Preliminary Fourth Quarter And Full Year 2025 Results</title></head><body><p><span>Jan 13 (Reuters)</span><span> - </span>TG Therapeutics Inc <span>TGTX.O</span>:</p><ul><li><p>TG THERAPEUTICS PROVIDES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2025 NET PRODUCT REVENUE AND 2026 REVENUE GUIDANCE AND ANTICIPATED DEVELOPMENT MILESTONES</p></li><li><p>TG THERAPEUTICS INC - 2026 GLOBAL REVENUE TARGET $875-900 MILLION, BRIUMVI U.S. $825-850 MILLION</p></li><li><p>TG THERAPEUTICS INC - PHASE 1 AZER-CEL DATA IN PROGRESSIVE MS EXPECTED SECOND HALF 2026</p></li></ul><p>Source text: <span>ID:nGNX6BPwLK</span></p><p>Further company coverage: <span>TGTX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Tg Therapeutics Provides Preliminary Fourth Quarter And Full Year 2025 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Tg Therapeutics Provides Preliminary Fourth Quarter And Full Year 2025 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-14 06:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Tg <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Provides Preliminary Fourth Quarter And Full Year 2025 Results</title></head><body><p><span>Jan 13 (Reuters)</span><span> - </span>TG Therapeutics Inc <span>TGTX.O</span>:</p><ul><li><p>TG THERAPEUTICS PROVIDES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2025 NET PRODUCT REVENUE AND 2026 REVENUE GUIDANCE AND ANTICIPATED DEVELOPMENT MILESTONES</p></li><li><p>TG THERAPEUTICS INC - 2026 GLOBAL REVENUE TARGET $875-900 MILLION, BRIUMVI U.S. $825-850 MILLION</p></li><li><p>TG THERAPEUTICS INC - PHASE 1 AZER-CEL DATA IN PROGRESSIVE MS EXPECTED SECOND HALF 2026</p></li></ul><p>Source text: <span>ID:nGNX6BPwLK</span></p><p>Further company coverage: <span>TGTX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA3RVHL:1","article_id":"2603553376","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603553376","pubTimestamp":1768343071,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Tg Therapeutics Provides Preliminary Fourth Quarter And Full Year 2025 ResultsJan 13 (Reuters) - TG Therapeutics Inc TGTX.O:TG THERAPEUTICS PROVIDES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2025","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4139":"生物科技","BK4585":"ETF&股票定投概念","TGTX":"TG Therapeutics Inc."},"translate_title":"简介-Tg Therapeutics提供2025年第四季度和全年初步业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TGTX":0.9},"content_text":"BRIEF-Tg Therapeutics Provides Preliminary Fourth Quarter And Full Year 2025 ResultsJan 13 (Reuters) - TG Therapeutics Inc TGTX.O:TG THERAPEUTICS PROVIDES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2025 NET PRODUCT REVENUE AND 2026 REVENUE GUIDANCE AND ANTICIPATED DEVELOPMENT MILESTONESTG THERAPEUTICS INC - 2026 GLOBAL REVENUE TARGET $875-900 MILLION, BRIUMVI U.S. $825-850 MILLIONTG THERAPEUTICS INC - PHASE 1 AZER-CEL DATA IN PROGRESSIVE MS EXPECTED SECOND HALF 2026Source text: ID:nGNX6BPwLKFurther company coverage: TGTX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603553376","isCrawlerRequest":true}